Marqibo vincristine: Final Phase II data

Final data from the open-label, international, pivotal Phase II rALLy trial in 65 patients with Philadelphia chromosome-negative ALL in second or greater relapse showed that 2.25 mg/m 2 weekly IV Marqibo had an overall response rate (ORR) of 35%, with 20% of patients achieving a CR or CRi. Estimated median OS was 4.6 months for all patients and 7.4 months in complete responders. Estimated median duration of CR/CRi was 5.3 months in responders. Data were presented at the American Society of Clinical Oncology meeting in Chicago. ...